5-α reductase inhibitors and prostate cancer prevention: where do we turn now? by Hamilton, Robert J & Freedland, Stephen J
COMMENTARY Open Access
5-a reductase inhibitors and prostate cancer
prevention: where do we turn now?
Robert J Hamilton
1,2 and Stephen J Freedland
2,3*
Abstract
With the lifetime risk of being diagnosed with
prostate cancer so great, an effective
chemopreventive agent could have a profound
impact on the lives of men. Despite decades of
searching for such an agent, physicians still do not
have an approved drug to offer their patients. In this
article, we outline current strategies for preventing
prostate cancer in general, with a focus on the 5-a-
reductase inhibitors (5-ARIs) finasteride and
dutasteride. We discuss the two landmark
randomized, controlled trials of finasteride and
dutasteride, highlighting the controversies stemming
from the results, and address the issue of 5-ARI use,
including reasons why providers may be hesitant to
use these agents for chemoprevention. We further
discuss the recent US Food and Drug Administration
ruling against the proposed new indication for
dutasteride and the change to the labeling of
finasteride, both of which were intended to permit
physicians to use the drugs for chemoprevention.
Finally, we discuss future directions for 5-ARI research.
Introduction
Prostate cancer is the most commonly diagnosed cancer
among men and the second leading cause of cancer
death [1]. With one in six men destined to be diagnosed
with prostate cancer in their lifetimes and the costs
associated with prostate cancer care being very high [2],
the potential benefits of an effective chemoprevention
agent are obvious [1]. Yet, despite decades of research
in the field, there are still no approved pharmaceuticals
for the prevention of prostate cancer. The 5-a reductase
inhibitors (5-ARIs) finasteride and dutasteride are the
most promising to date, but also the most controversial.
Recently, the US Food and Drug Administration (FDA)
ruled against proposals to add an indication to dutaste-
ride and alter the labeling of finasteride that would
allow prescribers to use these drugs for chemopreven-
tion. The impact of this decision on the future of pros-
tate chemoprevention remains to be seen. Is it the nail
in the coffin or the needed wake-up call to turn the
field in another direction?
In this article, we outline strategies for preventing
prostate cancer in general, but focus specifically on the
5-ARIs. We discuss the two landmark randomized, con-
trolled trials (RCTs) of finasteride and dutasteride and
highlight the controversies stemming from the results.
We address the issue of 5-ARI use and why providers
may be hesitant to use these agents for chemopreven-
tion, as well as the recent FDA ruling.
Preventing prostate cancer
Over the years, several nutrients, lifestyle modifications
and pharmaceutical agents have been studied as poten-
tial chemoprevention candidates [3]. Selenium and vita-
min E showed promise [4,5]. However, these were
definitively evaluated in the Selenium and Vitamin E
Cancer Prevention Trial, and neither agent reduced
prostate cancer risk [6]. Vitamin D analogs, nonsteroidal
anti-inflammatory drugs (NSAIDs) and toremifene (a
selective estrogen receptor modulator) have all been
evaluated in laboratory and/or observational studies
[7-9]. However, vitamin D has not been formally tested
in primary prevention trials. An attempt was made to
study the NSAID rofecoxib, but the trial was closed
when the drug was taken off the market for safety rea-
sons [10]. Toremifene showed a modest risk reduction
in a phase II trial [11], but no significant risk reduction
in a phase III trial [12].
Statin medications hold promise for prostate cancer
prevention. They appear to reduce prostate-specific anti-
gen (PSA) [13,14], and while they do not apparently
reduce prostate cancer risk overall, they appear to
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prostate cancer [15]. They are also associated with
improved outcomes after radiation therapy [16] and
radical prostatectomy [17], though data for the latter are
conflicting [18]. The advantage of statins is their proven
safety record and their welcome side effects of decreased
cholesterol levels and cardiac disease risk reduction.
Though no trial of the use of statins in primary prostate
cancer prevention is currently underway, two studies of
statins as secondary preventive agents are. One trial is
randomizing patients to simvastatin or placebo prior to
radical prostatectomy and is examining changes in
benign and malignant tissue in the prostate specimen
[19]. The second trial is a phase II study of atorvastatin
and celecoxib in patients with rising PSA levels after
definitive local therapy and is examining changes in bio-
markers, including PSA [20].
Taken together, the medical community is unlikely to
have a compound with proven ability to prevent pros-
tate cancer emanate from these studies in the forseeable
future.
The 5-a reductase inhibitors
Rationale and benefits
By far the most promising and well-studied chemopreven-
tive agents are the 5-ARIs finasteride and dutasteride. The
5-a reductase (5-AR) enzyme is responsible for converting
testosterone into dihydrotestosterone. Dihydrotestosterone
is a prevalent and potent androgen in prostate tissue and
is responsible for embryologic development of the prostate
[21], growth of the prostate and promotion of prostate
cancer [22]. Finasteride inhibits 5-AR type 2, and dutaste-
ride inhibits 5-AR types 1 and 2. Both finasteride and
dutasteride were designed and approved for the treatment
of benign prostatic hyperplasia (BPH) and have proven
efficacy in this regard [23-26].
Finasteride was studied in the Prostate Cancer Preven-
tion Trial (PCPT) [27]. In this RCT of 18,000 men ≥ 55
years of age with a normal digital rectal examination
(DRE) and PSA level ≤ 3 ng/mL, after seven years, those
in the finasteride arm had a 25% reduction in prostate
cancer incidence (18.4% vs. 24.4%; P < 0.001). Dutaste-
ride was studied in the REduction by DUtasteride of
Prostate Cancer Events (REDUCE) trial [28]. In this
R C To f6 , 7 2 9m e na g e s5 0t o7 5y e a r sw i t hap r i o r
negative prostate biopsy who had at least one on-study
biopsy, those in the dutasteride arm had a 23% reduc-
tion in prostate cancer incidence after four years (19.9%
vs. 25.1%; P < 0.001). The two trials are compared in
Table 1. These risk reductions translate into a number
needed to treat to prevent one case of prostate cancer
of 17 for finasteride and 20 for dutasteride. If the story
ended there, many men would undoubtedly be taking a
5-ARI drug today.
The controversy
Unfortunately, the results of the two primary preven-
tion trials are more complicated. First, these trials
have been criticized for lack of generalizability because
t h er e s u l t sw e r ed r i v e nl a r g e l yb ye n d - o f - s t u d yb i o p -
sies as opposed to biopsies clinically triggered by ele-
vated PSA or DRE abnormalities. In fact, subgroup
analyses of only biopsies triggered by clinical events
suggested 5-ARIs achieved less impressive relative risk
reductions (RRRs) (PCPT: 9% RRR; REDUCE: 1%
RRR) [27,28]. It is argued that these risk reduction
estimates more closely mirror what would be seen in
general practice.
Second, it appears that 5-ARIs preferentially prevent
low-grade cancers. In both trials, the overall cancer risk
reduction was driven entirely by the reduction in Glea-
son ≤ 6 tumors. Such low-grade cancers are unlikely to
lead to prostate cancer mortality and thus arguably do
not warrant preventive efforts [29,30]. Indeed, a patholo-
gical review of cancers in the PCPT demonstrated that
40% of the Gleason ≤ 6 tumors met established patholo-
gic criteria for clinically insignificant disease [31,32]. A
similar analysis of the REDUCE trial cancers has yet
been published; however, a pathologic review by an
expert genitourinary pathologist commissioned by the
FDA concluded that 80% of the Gleason ≤ 6t u m o r s
met the criteria for clinically insignificant disease [33].
Two counterarguments are apparent: (1) In general, as
many as 30% of cancers initially deemed insignificant on
the basis of the first biopsy are reclassified as significant
o nt h eb a s i so fas u b s e q u e n tb i o p s y[ 3 4 ] ;a n d( 2 )c u r -
rently in the United States, > 90% of men diagnosed
with Gleason 6 tumors undergo surgery or radiotherapy
[35]. If these trends continue, reducing the incidence of
these often-treated cancers with 5-ARIs may be
meaningful.
By far the issue receiving the greatest concern from
these two prevention trials is the increased risk of high-
grade disease. In the PCPT, the proportion of high-
grade tumors (Gleason ≥ 7) was 27% higher in the finas-
teride arm (280 (6.4%) vs. 237 (5.1%); P = 0.005), and in
the REDUCE trial, though no significant difference in
Gleason ≥ 7 tumors was reported (220 (6.7%) vs. 233
(6.8%); P = 0.81), there was clearly a trend toward
increased risk in Gleason ≥ 8t u m o r s( 2 9( 0 . 9 % )v s .1 9
(0.6%); P = 0.15), particularly in years 3 and 4 (12 (0.5%)
vs. 1 (< 0.1%); P = 0.003).
Two theories have been suggested as to why higher-
grade disease is noted in the 5-ARI arms: (1) 5-ARIs
shrink prostate volume, thus making it more likely to
find high-grade disease when it is present [36]; and (2)
5-ARIs, by reducing confounding from BPH, heighten
the sensitivity of the PSA and DRE in the detection of
high-grade disease [37,38]. In a post hoc analysis using
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Page 2 of 7Table 1 Comparison of the two randomized controlled trials of 5-a reductase inhibitors for primary prevention of
prostate cancer
a
PCPT REDUCE
Agent studied Finasteride 5 mg Dutasteride 0.5 mg
Manufacturer Merck & Co., Inc. GlaxoSmithKline
Enzyme inhibition 5-AR type 2 5-AR types 1 and 2
Study size 18,882 8,231
Final analysis size, (drug:
placebo)
9,060 (4,368:4,692) 6,729 (3,305:3,424)
Follow-up 7 years 4 years
Eligibility criteria Age ≥55 years Age 50 to 75
Normal DRE PSA 2.5 to 10 ng/mL
PSA ≤3 ng/mL Prior negative prostate biopsy (6-core minimum) within 6
months
AUA Symptom Score <20 AUA Symptom Score <25 (or <20 if taking a blockers)
Excluded if
HGPIN
ASAP
> 1 biopsy prior
Gland volume > 80 cm
3
In-study measures Annual PSA, DRE Semiannual PSA, DRE
Finasteride PSA adjusted by 2× to 2.3× Dutasteride PSA adjusted by 2×
Triggers for biopsy Triggers for biopsy
Abnormal DRE Not specified
PSA > 4 ng/mL Protocol biopsies at 2 and 4 years
End-of-study biopsy offered to all without cancer after 7
years
Biopsies for cause, % 39.4% 12.0%
Primary end point Prostate cancer detection Prostate cancer detection
Finasteride 803 (18.4%) Dutasteride 659 (19.9%)
Placebo 1,147 (24.4%) Placebo 858 (25.1%)
RRR = 24.8%, 95% CI 18.6 to 30.6; P < 0.001 RRR = 22.8%, 95% CI 15.2 to 29.8, P < 0.001
Secondary end points Prostate volume at biopsy Change in prostate volume from years 1 to 4
Finasteride = 25.5 cm
3 Dutasteride 45.7 to 39.0 cm
3 = -17.5%
Placebo = 33.6 cm
3 Placebo 45.8 to 56.2 cm
3 = +19.7%
Relative difference = 24.1% Relative difference in final volume = 30.1%
HGPIN
Dutasteride 3.7%
Placebo 6.0%
RRR = 39.2%, 95% CI 24.2-51.1, p<0.001
ASAP
Dutasteride 3.8%
Placebo 4.9%
RRR = 21.2%, 95% CI 1.3-37.1, p = 0.04
High-grade disease Gleason ≥7 detection Gleason ≥7 detection
Finasteride 280 (6.4%) Dutasteride 220 (6.7%)
Placebo 237 (5.1%) Placebo 233 (6.8%)
RR = 1.67, 95% CI 1.44-1.93, p = 0.005 RR = 1.02, p = 0.81
Gleason ≥8 detection Gleason ≥8 detection
Finasteride 90 (2.1%) Dutasteride 29 (0.9%)
Placebo 53 (1.1%) Placebo 19 (0.6%)
RR = 1.90; 95% CI and P value not given RR = 1.5, 95% CI not given, P = 0.15
NNT to prevent 1 cancer 17 20
a5-AR: 5-a reductase enzyme; 5-ARIs: 5-a reductase inhibitors; ASAP: atypical small acinar proliferation; AUA: American Urological Association; DRE: digital rectal
examination; HGPIN: high-grade prostatic intraepithelial neoplasia; NNT: number needed to treat; RR: relative risk; RRR: relative risk reduction; 95% CI: 95%
confidence interval.
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Page 3 of 7imputation based on these two theories, the PCPT
group concluded that there was actually a 27% reduc-
tion in the risk of Gleason ≥ 7t u m o r s ,t h o u g ht h e r e
remained, albeit reduced, a 25% increase in risk of
Gleason ≥ 8 tumors [39]. In the REDUCE study, the
authors explained that the increased risk of Gleason ≥
8 tumors was a product of more cancers being
detected in the placebo group in years 1 and 2. That
is, if these tumors were not detected and therefore not
removed from analysis in years 3 and 4, a portion of
them would have progressed to high-grade disease and
would have balanced the higher-grade tumors seen in
the dutasteride arm in years 3 and 4. However, the
natural history of low-grade tumors dedifferentiating
to high-grade tumors is not known and unlikely to be
sufficiently rapid to explain the difference in years 3
and 4.
The fact remains that both trials observed at least
concerning trends toward increased high-grade disease,
though it should be noted that the absolute risk increase
is small. The true extent to which these trends can be
explained by the theories proposed is unknown, but for
now concern lingers that 5-ARIs may induce or selec-
tively promote growth of high-grade disease.
Use of 5-a reductase inhibitors in practice
T h eo n l ys t u d ye x p l o r i n gt h eu s eo f5 - A R I si nc l i n i c a l
practice observed that while use slowly increased from
2000 to 2005 in the Veterans Health Administration,
there was a subtle trend toward decreased use after pub-
lication of the PCPT (Figure 1) [40]. This change did
not reach statistical significance, and prescriptions could
not be classified by intended use (prostate cancer pre-
vention vs. treatment of BPH).
In the accompanying survey, urologists cited concerns
over the risk of high-grade disease as the most common
reason not to prescribe 5-ARIs for chemoprevention
[40]. This article was written prior to the publication of
the REDUCE trial. As such, the extent to which 5-ARIs
are currently being used for prostate cancer prevention
remains unclear.
Most recently, the FDA Oncology Drugs Advisory
Committee (ODAC) reviewed applications by GlaxoS-
mithKline to add an indication for dutasteride for the
prevention of prostate cancer in men at increased risk
for prostate cancer and by Merck to alter the labeling
for finasteride to reflect a more favorable safety profile
with regard to preventing prostate cancer. The FDA
conducted its own reanalysis of the PCPT and REDUCE
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Figure 1 Number of new finasteride users among Veterans Health Administration (VHA) patients from January 2000 to October 2005,
before and after publication of the PCPT, adjusted for changes in the size and age of the male VHA population over time (adapted
from Hamilton et al. [40]).
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Page 4 of 7trial results and concluded that (1) the risks of high-
grade cancer were likely real and could not be explained
entirely by volume grade bias, increased sensitivity of
PSA and DRE or removal of low-grade cancers in the
REDUCE trial placebo arm, (2) the majority of cancers
prevented were low risk and the trials provided no evi-
dence of 5-ARI treatment and prostate cancer mortality
reduction and (3) the results were not generalizable to
the US population because end-of-study biopsies do not
mirror clinical practice. The FDA ODAC voted against
the new indication for dutasteride (yes = 2, no = 14,
abstain = 2) and against the new labeling for finasteride
(yes = 0, no = 17, abstain = 1). GlaxoSmithKline has
subsequently announced that it is withdrawing applica-
tions for similar approval in other countries [41].
Though we do not have an up-to-date assessment of
whether 5-ARIs are being prescribed for chemopreven-
tion, it is likely, given trepidation before, that the FDA
ruling will lead to more hesitation in prescribing 5-ARIs
for this indication. Apparent from the FDA ODAC
meeting was that even among people who study the
issue of 5-ARI chemoprevention extensively, eight years
after publication of the PCPT there is still vast disagree-
ment regarding the benefits and harms. With such dis-
agreement among experts, it is not surprising that
practicing physicians do not have a clear answer when
their patients ask about 5-ARIs.
Cost-effectiveness
Since the PCPT, 11 publications have explored various
aspects of the trade-offs among the benefits, harms and
costs of 5-ARI chemoprevention for prostate cancer. An
extensive analysis of these s t u d i e si sb e y o n dt h es c o p e
of this review and is complicated by the fact that each is
based on a set of assumptions about the PCPT data. For
example, some model the risk of high-grade disease at
face value from the trial; others impute less risk of high-
grade disease based on the volume grade and PSA sensi-
tivity biases; some model the baseline cancer risk from
all biopsies in the control arm, which include end-of-
study biopsies; and others use Surveillance Epidemiology
End Results rates to better approximate real-world inci-
dence. Overall, most conclude that a strategy whereby
all men over 55 years of age are recommended to take
finasteride is not cost-effective [42,43]. However, studies
analyzing a strategy targeting only men at higher risk of
prostate cancer suggest that finasteride chemoprevention
is cost-effective [44-47].
The goal of the REDUCE study was to examine 5-
ARIs in men at higher risk in hopes of answering that
question. As it turned out, that cohort of men with a
prior negative biopsy actually had a risk of prostate can-
cer equal to that of the PCPT cohort (placebo cancer
rate 24.4% in PCPT vs. 25.1% in REDUCE). Only one
study has examined the cost-effectiveness of dutasteride
based on the REDUCE data and similarly concluded
that it is unlikely to be cost-effective unless targeted at a
high-risk population [48].
Future directions
Given the tremendous potential benefits of chemopre-
vention, there is logic in searching for a different role
for 5-ARIs. Indeed, more derivative questions are still
being addressed in trials. For example, investigators are
studying whether short courses of finasteride improve
the discriminating ability of PSA in prostate cancer
screening [49] or the cancer yield at repeat biopsy after
a prior negative biopsy [50], as well as whether dutaste-
ride prevents cancer in men with high-grade prostate
intraepithelial neoplasia, a precursor lesion to prostate
cancer [51]. Aside from these trials, more work is
needed to identify a subgroup of patients, using either
clinical or genetic features, who are at increased risk of
prostate cancer and/or are most likely to respond to 5-
ARI therapy. Perhaps we can identify a genetic signature
that predicts those prone to developing high-grade dis-
ease in the dihydrotestosterone-depleted prostate envir-
onment, and physicians could avoid using 5-ARIs in
these men. Selective treatment in men without this sig-
nature would be “safer” in that it only reduces prostate
cancer risk without increasing high-grade disease.
It may be that 5-ARIs are more appropriate for sec-
ondary prevention, that is, in preventing adverse out-
comes in men who already have been diagnosed with
cancer. The Reduction by Dutasteride of Clinical Pro-
gression Events in Expectant Management (ReDEEM)
trial has now concluded. Presented only in abstract form
to date, this study illustrated that in men with very low-
risk prostate cancer treated with active surveillance,
dutasteride reduced the time to pathologic or therapeu-
tic progression by 38.9% (95% confidence interval 12.4
to 57.4; P = 0.007) [52].
Conclusions
With the risk of prostate cancer so high, there is great
need for a strategy to reduce the incidence and thus the
burden of prostate cancer. Chemoprevention holds such
potential in this regard. Yet, the future of 5-ARIs, the
most promising chemopreventive agents to date, is
uncertain. In the role of wide-scale use to prevent pros-
tate cancer in men of average risk, this is likely the end
for 5-ARIs with no further primary prevention trials on
the horizon. The widespread acceptance of statins and
aspirin for cardiovascular disease prevention proves that
patients are willing to take a drug to prevent a disease
they may never get. In the case of 5-ARIs, it is likely not
the small risk of reversible sexual side effects or the pre-
ferential prevention of low-grade disease that are
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lingering uncertainty surrounding the risk of high-grade
disease. No physician or regulatory body is comfortable
treating healthy men with a drug that has even the
slightest risk of inducing a potentially lethal cancer.
Until more is learned, physicians are unfortunately left
in the difficult position of explaining the complicated
risks and benefits of 5-ARIs, and while they were never
approved for chemopreventive use before, there was
always the hope that they would be. Now the hope of
their approval is gone, and the scientific community,
while still endeavoring to identify a specific subgroup of
men who will benefit from 5-ARIs, should begin turning
the page toward the next chemoprevention strategy.
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